3-point major cardiovascular event outcome for patients with T2D treated with dipeptidyl peptidase-4 inhibitor or glucagon-like peptide-1 receptor agonist in addition to metformin monotherapy
@article{ATM55933, author = {Caroline E. El Sanadi and Xinge Ji and Michael W. Kattan}, title = {3-point major cardiovascular event outcome for patients with T2D treated with dipeptidyl peptidase-4 inhibitor or glucagon-like peptide-1 receptor agonist in addition to metformin monotherapy}, journal = {Annals of Translational Medicine}, volume = {8}, number = {21}, year = {2020}, keywords = {}, abstract = {}, issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/55933} }